Resolution of macular edema in Coats' disease with intravitreal bevacizumab.
A 13-year-old boy was referred because of visual deterioration in his right eye. The visual acuity was two meters of counting fingers. Indirect ophthalmoscopy and biomicroscopy revealed exudative macular edema as well as tumor-like telangiectatic vessels and exudation in temporal periphery. With diagnosis of Coats' disease (stage II) confirmed by fluorescein angiography, three intravitreal injections of bevacizumab were performed at 6-week intervals. One year after the last injection, there was a significant resolution of macular edema as well as visual acuity improvement to 20/20. This is the first case report in which a distinct improvement in macular edema was observed with intravitreal bevacizumab in Coats' disease.
Entezari
Morteza
M
Department of Opthomology, Ophthalmic Research Centre, Shahid Beheshti University (M.C.), Tehran, Iran.
Ramezani
Alireza
A
Safavizadeh
Ladan
L
Bassirnia
Nader
N
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003937:Diagnosis, Differential; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D033401:Microscopy, Acoustic; D009887:Ophthalmoscopy; D012164:Retinal Diseases / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D012171:Retinal Vessels / Q000473:pathology*; D013684:Telangiectasis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab